Abstract
6-Sulfatoxymelatonin (aMT6s) is the main metabolite of melatonin in urine, and is a reliable surrogate biomarker reflecting the blood melatonin concentration. This meta-analysis assessed the association between urinary aMT6s level and BC incidence. The electronic databases PubMed, EMBASE, Cochrane Library, and Web of Science were searched. Risk ratios (RRs) were adopted to estimate the relative BC incidence. A total of 7 prospective case-control publications were included, and 6 of them were distinct studies. Pooled analysis of data from the 6 studies involving 1824 women with incident BC and 3954 matched control participants with no overlapping of subjects among studies indicated no significant association between the highest levels of urinary aMT6s and the incidence of BC (RR = 0.97, 95% CI, 0.88–1.08, P = 0.56). Negative associations were observed in postmenopausal women (RR = 0.88, 95% CI, 0.75–1.02, P = 0.10), estrogen receptor positive BC (RR = 0.83, 95% CI, 0.64–1.07, P = 0.15), and studies using 12-hour overnight urine (RR = 0.81, 95% CI, 0.61–1.07, P = 0.13), all with borderline significances. Lag time or invasive degree did not interfere with the results. There was no evident publication bias detected by the Egger’s test and the funnel plot. Conclusively, the current evidence did not support a significant association between urinary aMT6s level and BC risk.
Highlights
Breast cancer (BC) is one of the most common malignancies and a leading cause of cancer-related mortality among women worldwide[1, 2]
There was no evidence of statistical association between urinary aMT6s and BC risk, which was inconsistent with the previous reports[21, 23]
We revealed no significant link between aMT6s and BC risk (RR = 0.97, P = 0.56)
Summary
Breast cancer (BC) is one of the most common malignancies and a leading cause of cancer-related mortality among women worldwide[1, 2]. Basler et al.[23] found a weak but statistically significant inverse association between the urinary aMT6s level and BC risk (RR = 0.82, 95% CI, 0.68–0.99, P = 0.04) based on only 5 studies[13, 16,17,18,19]. Basler et al.[23] only searched one electronic database, suggesting an incomprehensive retrieval Their conclusions that melatonin affects BC incidence in women should be interpreted with caution and needs to be tested with the 3 emerging studies[20,21,22]. An up-dated meta-analysis and systematic review was conducted to further assess the possible relationship between melatonin and the risk of BC based on studies investigating the urinary aMT6s concentrations
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
